Form 4: Cocrystal Pharma Co-CEO Buys Shares & Warrants

Cocrystal Pharma's Co-CEO and CFO, James Joseph Martin, acquired 3,598 shares of common stock and 7,196 warrants in a recent transaction.

Summary

• James Joseph Martin, Co-CEO and CFO of Cocrystal Pharma, Inc. (COCP), acquired 3,598 shares of common stock and 7,196 warrants.
• The transaction occurred on October 28, 2025.
• The units were purchased at $1.39 per unit, with each unit comprising one share of common stock and a warrant to purchase two shares of common stock.
• Each warrant has an exercise price of $1.24 and expires on January 28, 2028.
• Following the transaction, Martin beneficially owns 44,167 shares of common stock (including shares issuable upon vesting of restricted stock units) and 7,196 warrants.
• The transaction was approved by a Special Committee of the Board of Directors, consisting of two non-employee directors, exempting it from Section 16(b) of the Securities Exchange Act of 1934 under Rule 16b-3.

Sentiment

Score: 8

Explanation: The direct purchase of common stock and warrants by a key executive (Co-CEO and CFO) indicates strong insider confidence in the company's future performance and valuation, which is generally viewed as a positive signal by the market.

Positives

• Co-CEO and CFO James Joseph Martin increased his direct ownership in Cocrystal Pharma, Inc. by acquiring 3,598 shares of common stock and 7,196 warrants, signaling strong confidence in the company's future.
• The transaction was structured as a purchase of units at $1.39 per unit, demonstrating a direct financial commitment from a key executive.
• The acquisition of warrants, exercisable at $1.24 and expiring in January 2028, provides additional upside potential for the executive, aligning his interests with long-term shareholder value.
• The transaction was approved by a Special Committee of the Board of Directors, composed of non-employee directors, ensuring independent oversight and compliance with Rule 16b-3, which exempts the transaction from short-swing profit rules.

Future Outlook

NA

Management Comments

• The direct purchase of common stock and warrants by Co-CEO and CFO James Joseph Martin reflects management's confidence in the company's valuation and future prospects.

Industry Context

This Form 4 filing reports an insider transaction, which is specific to the company and its executive's investment decisions, rather than reflecting broader industry trends. However, insider buying can be a positive signal within the biotechnology and pharmaceutical sectors, where R&D success and pipeline value are key drivers.

Corporate Governance

Related Party Transactions

• James Joseph Martin, Co-CEO and CFO, acquired common stock and warrants from the issuer, which constitutes a related party transaction.
• The transaction was explicitly approved by a Special Committee of the Board of Directors, composed of non-employee directors, to ensure fairness and compliance with regulatory requirements.

Stakeholder Impact

• **Shareholders:** The insider purchase by a key executive (Co-CEO and CFO) typically signals management's confidence in the company's prospects, which can be viewed positively by existing and potential shareholders. It aligns management's interests more closely with shareholder value creation.
• **Employees:** While not directly impacted, a confident management team can foster a more stable and positive work environment.

Key Dates

Recommendation

The direct purchase of common stock and warrants by a high-ranking executive like the Co-CEO and CFO signals strong insider confidence in the company's future prospects and valuation. Such insider buying often precedes positive developments and aligns management's interests with shareholders, making it a compelling signal for potential investors.

Keywords

Cocrystal Pharma, COCP, Insider Buying, Form 4, Executive Stock Purchase, Warrants, Biotechnology, Pharmaceuticals